Literature DB >> 17163231

Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers.

Keith G Tolman1, Jörg Täubel, Steven Warrington, Yi-Lin Chiu, Betsy L Pilmer, Wei-Jian Pan.   

Abstract

BACKGROUND: As the comparative pharmacokinetics and pharmacodynamics of lansoprazole and rabeprazole have not previously been studied, we set out in this study to compare the pharmacokinetics and pharmacodynamics of single and repeated daily doses of lansoprazole 15 mg and 30 mg with those of rabeprazole 10 mg and 20 mg.
METHODS: This was an open-label, randomised, crossover, two-centre study in 72 healthy volunteers. Each subject received each of the four treatments for 5 days, with 2-week washout periods. Continuous 24-hour intragastric pH and pharmacokinetics were studied on days 1 and 5.
RESULTS: Mean 24-hour pH and percentage time for pH > 4 were not significantly different between lansoprazole 30 mg and rabeprazole 20 mg. Mean 24-hour pH and percentage time for pH > 4 were significantly greater after lansoprazole 30 mg and rabeprazole 20 mg than after lansoprazole 15 mg and rabeprazole 10 mg, respectively. Lansoprazole resulted in greater acid suppression during hours 0-5 on days 1 and 5, whereas rabeprazole had greater suppression during hours 11-24 on day 5. Time to maximum plasma concentration was significantly shorter for lansoprazole on both days.
CONCLUSION: Lansoprazole had a consistently faster onset of action, whereas rabeprazole had a greater effect during the evening hours after 5 days of administration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163231     DOI: 10.2165/00044011-200626010-00003

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  18 in total

1.  Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.

Authors:  H G Dammann; W Fuchs; G Richter; F Burkhardt; N Wolf; T A Walter
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

2.  International variations in mortality from motor vehicle accidents.

Authors: 
Journal:  Stat Bull Metropol Life Insur Co       Date:  1979 Apr-Jun

3.  Integrated acidity and the pathophysiology of gastroesophageal reflux disease.

Authors:  J D Gardner; S Rodriguez-Stanley; M Robinson
Journal:  Am J Gastroenterol       Date:  2001-05       Impact factor: 10.864

4.  Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.

Authors:  N J Bell; R H Hunt
Journal:  Aliment Pharmacol Ther       Date:  1996-12       Impact factor: 8.171

5.  Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression.

Authors:  D W Burget; S G Chiverton; R H Hunt
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

6.  Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.

Authors:  Philip Miner; Philip O Katz; Yusong Chen; Mark Sostek
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

7.  A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.

Authors:  M P Williams; J Sercombe; M I Hamilton; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1998-11       Impact factor: 8.171

8.  Appropriate acid suppression for the management of gastro-oesophageal reflux disease.

Authors:  N J Bell; D Burget; C W Howden; J Wilkinson; R H Hunt
Journal:  Digestion       Date:  1992       Impact factor: 3.216

9.  Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.

Authors:  S Bruley des Varannes; P Levy; S Lartigue; F Dellatolas; M Lemaire; J P Galmiche
Journal:  Aliment Pharmacol Ther       Date:  1994-06       Impact factor: 8.171

10.  Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.

Authors:  D Pantoflickova; G Dorta; M Ravic; P Jornod; A L Blum
Journal:  Aliment Pharmacol Ther       Date:  2003-06-15       Impact factor: 8.171

View more
  5 in total

Review 1.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

2.  The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole.

Authors:  Jeong Hoon Lee; Hwoon-Yong Jung; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

Review 3.  Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.

Authors:  Shlomi Cohen; Mirjam Bueno de Mesquita; Francis B Mimouni
Journal:  Br J Clin Pharmacol       Date:  2015-06-11       Impact factor: 4.335

Review 4.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

5.  A review of rabeprazole in the treatment of acid-related diseases.

Authors:  Fabio Pace; Stefano Pallotta; Stefania Casalini; Gabriele Bianchi Porro
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.